Literature DB >> 26068660

Endothelin Receptor Antagonists: New Hope for Renal Protection?

Sheldon Tobe1, Donald E Kohan, Ranjit Singarayer.   

Abstract

Endothelin receptor antagonists (ERAs) have the potential to be a new paradigm in the treatment of chronic kidney disease (CKD). ERAs inhibit the effects of endothelin-1 (ET-1), which is known to promote CKD by causing renal cellular injury, proteinuria, inflammation, fibrosis, and hypertrophy. ERAs have been extensively studied preclinically in models of CKD and now in a large clinical trial to determine their effect on slowing the progression of CKD. Initial clinical trials show promise with regard to ERA effects on reducing proteinuria in patients with diabetic nephropathy (DN) who are already on renin-angiotensin system (RAS) blocking agents. A common side effect of peripheral edema has been consistently reported in clinical trials using ERAs; hence, finding a safe balance between renoprotective actions and side effects needs to be achieved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26068660     DOI： 10.1007/s11906-015-0568-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


  60 in total

Review 1.  Endothelin role in kidney acidification.

Authors:  Donald E Wesson
Journal:  Semin Nephrol       Date:  2006-09       Impact factor: 5.299

2.  Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension.

Authors:  L V d'Uscio; P Moreau; S Shaw; H Takase; M Barton; T F Lüscher
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

Review 3.  Role of endothelin-1 in hypertension and vascular disease.

Authors:  E L Schiffrin
Journal:  Am J Hypertens       Date:  2001-06       Impact factor: 2.689

4.  Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue.

Authors:  C Zoja; S Orisio; N Perico; A Benigni; M Morigi; L Benatti; A Rambaldi; G Remuzzi
Journal:  Lab Invest       Date:  1991-01       Impact factor: 5.662

5.  Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).

Authors:  Dennis L Andress; Blai Coll; Yili Pritchett; John Brennan; Mark Molitch; Donald E Kohan
Journal:  Life Sci       Date:  2012-02-02       Impact factor: 5.037

6.  Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy.

Authors:  J S Li; R Larivière; E L Schiffrin
Journal:  Hypertension       Date:  1994-08       Impact factor: 10.190

7.  Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.

Authors:  Ovidiu C Baltatu; Christian E Zaugg; Christoph Schumacher; Pat Louie; Luciana A Campos; Michael Bader
Journal:  Pharmacol Res       Date:  2013-12-22       Impact factor: 7.658

Review 8.  Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?

Authors:  Donald E Kohan; John G Cleland; Lewis J Rubin; Dan Theodorescu; Matthias Barton
Journal:  Life Sci       Date:  2012-08-06       Impact factor: 5.037

9.  Endothelin-induced endocytosis of cell surface ETA receptors. Endothelin remains intact and bound to the ETA receptor.

Authors:  M Chun; H Y Lin; Y I Henis; H F Lodish
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157

10.  High glucose alters actin assembly in glomerular mesangial and epithelial cells.

Authors:  X Zhou; R D Hurst; D Templeton; C I Whiteside
Journal:  Lab Invest       Date:  1995-09       Impact factor: 5.662
View more
  2 in total

1.  Endothelin-1 Immunoreactivity and its Association with Intramedullary Hemorrhage and Myelomalacia in Naturally Occurring Disk Extrusion in Dogs.

Authors:  D Mayer; A Oevermann; T Seuberlich; M Vandevelde; A Casanova-Nakayama; S Selimovic-Hamza; F Forterre; D Henke
Journal:  J Vet Intern Med       Date:  2016-06-29       Impact factor: 3.333

2.  Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium.

Authors:  Ewa Szczesny-Malysiak; Marta Stojak; Roberto Campagna; Marek Grosicki; Marek Jamrozik; Patrycja Kaczara; Stefan Chlopicki
Journal:  Oxid Med Cell Longev       Date:  2020-10-14       Impact factor: 6.543
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.